Holding(s) in Company

RNS Number : 8768Z

Immupharma PLC

20 March 2017

 

20 MARCH 2017

NOTIFICATION OF MAJOR INTEREST BY LEGAL & GENERAL

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc ("L&G") confirming its holding in ImmuPharma of  4,446,545 million Ordinary Shares in the capital of the Company, representing 3.35% of ImmuPharma's total voting rights figure of  132,522,985 Ordinary Shares.

Commenting, Tim McCarthy, Chairman of ImmuPharma, said: "We are delighted to be able to disclose Legal & General's increased holding in ImmuPharma as one of our existing major institutional investors which participated in our recent successful £4.1 million fundraising demonstrating its continued support for ImmuPharma."

Full disclosure of the TR1 is shown below:

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:			ImmuPharma Plc
2. Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights				Yes
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation:		Legal & General Group Plc (L&G)
4. Full name of shareholder(s)  (if different from 3.):		Legal & General Assurance Society Limited (LGAS)
5. Date of the transaction and date on which the threshold is crossed or reached:		16 March 2017
6. Date on which issuer notified:		17 March 2017
7. Threshold(s) that is/are crossed or reached:		L&G (Above 3%)

8. Notified details:

A: Voting rights attached to shares

Class/type of shares if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of  voting rights

Direct

Indirect

Direct

Indirect

ORD GBP 0.10

Below 3%

4,446,545

4,446,545

-

3.35%

-

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date

Exercise/ Conversion period

Number of voting rights instrument refers to

% of voting rights

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

(L&G) 4,446,545

3.35%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

Legal & General Group Plc (Direct and Indirect) (Group) ( Below 5% = Total Position) Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect)  ( Below 5% = Total Position) Legal & General Investment Management Limited (Indirect) (LGIM) ( Below 5% = Total Position) Legal & General Group Plc (Direct) (L&G) ( 4,446,545 -3.35% = LGAS,& PMC) Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD) Legal & General Insurance Holdings Limited (Direct) (LGIH) Legal & General Assurance (Pensions Management) Limited  (PMC) Legal & General Assurance Society Limited  (LGAS)

Proxy Voting:
10. Name of the proxy holder:		N/A
11. Number of voting rights proxy holder will cease to hold:		N/A
12. Date on which proxy holder will cease to hold voting rights:		N/A
13. Additional information:	Notification using the total voting rights figure of  132,522,985
14. Contact name:	Victoria Davies (LGIM)
15. Contact telephone number:	029 2035 4147

-Ends-

For further information please contact: ImmuPharma plc (www.immupharma.org) + 44 (0) 20 7152 4080 Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations Twitter: @immupharma + 44 (0) 7721 413496 Northland Capital Partners Limited (NOMAD & Broker) Patrick Claridge, David Hignell, Michael Mackintosh, Corporate Finance Rob Rees, Corporate Broking [phone]

 

END

 

 

HOLLKLFFDXFZBBB